Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
NCT03939312
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
685
Enrollment
INDUSTRY
Sponsor class
Conditions
Episodic Migraine
Interventions
DRUG:
Atogepant
Sponsor
Allergan